

Identifying and Preparing Patients for CAR-T Therapy

A Roadmap for Relapse/Refractory Multiple Myeloma Referral

The publication of this infographic was sponsored by Bristol Myers Squibb.



EMJ Hematol. 2024; <https://doi.org/10.33590/emjhematol/ABAR1708>.

Some key differences between immunotherapy options, such as CAR-T therapy and Bispecific Antibodies (BsAb) therapy


CAR-T therapy, like BsAb, is a T-cell redirection approach to MM treatment.¹ There are differences between the two therapy classes generally worth understanding.



Administration	
Single IV infusion ^{7,8,12,14,15}	Weekly or biweekly SC administration until disease progression ^{4-6,9-12}
Account for personalised manufacturing turnaround time (during which bridging therapy is recommended) and administered exclusively at certified treatment centres ^{3,13}	Immediate availability at local healthcare facilities, but requires step-up priming doses where patients need to be in proximity of the healthcare facility for monitoring ^{3-6,9-11}
Safety Profile	
CRS and ICANS were more common and more severe than with BsAbs in clinical trials ^{4-11,14}	CRS and ICANS were less common and less severe than with CAR-T therapy in clinical trials ^{4-11,14}
Risk of HLH/MAS, prolonged cytopenia, and secondary haematological malignancies ^{7,8,14,15}	
May have a less persistent infection risk and a lower incidence of severe infections compared with BsAbs ¹⁶	May have a more persistent infection risk and a higher incidence of severe infections compared with CAR-T therapy ¹⁶
Indication	
Indicated for RRMM use as early as the second or third line of therapy (among other requirements) ^{7,8,14,15}	Indicated for RRMM use at the fourth or fifth line of therapy (among other requirements) ^{4-7,9-11}

This table is for illustrative purposes. Direct comparison between different therapeutic drugs is not intended and should not be inferred in the absence of head-to-head prospective studies.

Patient Journey



Conclusion/Key Learnings

Start thinking about CAR-T therapy at an early stage of RRMM³

Collaboration between treating and referring centres is potentially critical to patient outcomes from CAR-T therapy

Having multiple treatment options enables tailored treatment and may benefit patient outcomes¹⁷

Abbreviations: BCMA: B-cell maturation antigen; BsAb: bispecific antibody; CAR-T: chimeric antigen receptor T-cell; CD3: cluster of differentiation 3; CRS: cytokine release syndrome; ECOG-PS: Eastern Cooperative Oncology Group performance status; HLH: haemophagocytic lymphohistiocytosis; HRQoL: health-related quality of life; ICANS: immune effector cell-associated neurotoxicity syndrome; MAS: macrophage activation syndrome; MM: multiple myeloma; RRMM: relapsed/refractory multiple myeloma. IV: intravenous SC: subcutaneous

References:
1. Pan D, Richter J. Teclistamab for multiple myeloma: clinical insights and practical considerations for a first-in-class bispecific antibody. *Cancer Manag Res.* 2023;15:741-751.
2. Ailawadhi S et al. Optimizing the CAR T-Cell therapy experience in multiple myeloma: clinical pearls from an expert roundtable. *Clin Lymphoma Myeloma Leuk.* 2024;24(5):e217-25.
3. Anderson LD et al. Chimeric antigen receptor T cell therapy for myeloma: where are we now and what is needed to move chimeric antigen receptor T cells forward to earlier lines of therapy? Expert panel opinion from the American Society for Transplantation and Cellular Therapy. *Transplant Cell Ther.* 2024;30(1):17-37.
4. Pfizer Inc. ELREXFIO (elranatamab) FDA prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761345Orig1s000lbl.pdf. Last accessed: 10 May 2024.
5. Janssen Biotech. TALVEY (talquetamab) FDA prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761342s000lbl.pdf. Last accessed: 10 May 2024.
6. Janssen Biotech. TECVAYLI (teclistamab) FDA prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761291s003lbl.pdf. Last accessed: 10 May 2024.
7. Janssen-Cilag International NV. CARVYKTI (ciltacabtagene autoleucl) EPAR prescribing information. 2023. Available at: <https://www.ema.europa.eu/en/medicines/human/EPAR/carvykti>. Last accessed: 7 June 2024
8. Bristol-Myers Squibb Pharma EEIG. ABECMA (idecabtagene vicleucl) EPAR prescribing information. 2024. Available at: <https://www.ema.europa.eu/en/medicines/human/EPAR/abecma>. Last accessed: 7 June 2024
9. Janssen-Cilag International N.V. TALVEY (talquetamab) EPAR prescribing information. 2024. Available at: <https://www.ema.europa.eu/en/medicines/human/EPAR/talvey>. Last accessed: 7 June 2024
10. Janssen-Cilag International N.V. TECVAYLI (teclistamab) EPAR prescribing information. 2024. Available at: <https://www.ema.europa.eu/en/medicines/human/EPAR/tecvayli>. Last accessed: 7 June 2024
11. Pfizer Europe. ELREXFIO (elranatamab) EPAR prescribing information. Available at: https://www.ema.europa.eu/en/documents/product-information/elrefxio-epar-product-information_en.pdf. Last accessed: 21 May 2024.
12. Acaster S et al. Impact of the treatment-free interval on health-related quality of life in patients with multiple myeloma: a UK cross-sectional survey. *Support Care Cancer.* 2013;21(2):599-607.
13. Bal S, Costa LJ. Bridging treatment prior to chimeric antigen receptor T-cell therapy in multiple myeloma. *Br J Haematol.* 2024;204(2):449-54.
14. Celgene. ABECMA (idecabtagene vicleucl) FDA prescribing information. Available at: <https://www.fda.gov/media/147055/download?attachment>. Last accessed: 10 May 2024.
15. Janssen Biotech. CARVYKTI (ciltacabtagene autoleucl) FDA prescribing information. Available at: <https://www.fda.gov/media/156560/download>. Last accessed: 10 May 2024.
16. Nath K et al. A comparative analysis of infectious complications in patients with multiple myeloma treated with BCMA-targeted bispecific antibodies and CAR T-cell therapy. *Blood.* 2023;14(2023)(Suppl 1): <https://ashpublications.org/blood/article/142/Supplement%201/1957/499960/A-Comparative-Analysis-of-Infectious-Complications>. Last accessed: 21 May 2024.
17. Terpos E et al. Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. *Blood Cancer J.* 2021;11(2):40.